FDA Approves Lucentis Biosimilar Nufymco - Top_Thought_Leaders - MDSpire

FDA Approves Lucentis Biosimilar Nufymco

Ranibizumab-leyk (Nufymco) is approved for all Lucentis indications.

  • By

  • Conexiant News Staff

  • January 2, 2026

  • 1 min

Share

Top Thought Leaders in Ophthalmology

Brief introduction explaining scope and methodology.

Original Source(s)

FDA Approves Lucentis Biosimilar Nufymco

  • by Conexiant News Staff

  • January 2, 2026

Related Content

Inner retinal layer thickness reflects plasma biomarkers in preclinical Alzheimer’s disease

Inside the Aging Eye

A comprehensive new Elsevier publication brings global expertise together to unpack how aging drives ocular structure, function, and disease

  • April 28, 2026

  • 2 min
FDA Monthly Preview: Key May Decisions to Watch

Several FDA decisions across multiple specialties are expected this month.